Tests elironrasib and daraxonrasib in advanced solid tumors with KRAS G12C mutation
Tests two drugs, alone and together, in adults with advanced KRAS G12C-mutated cancers.
Plain-language title generated from the registry record
Registry title: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Key facts
- Where
- Barcelona, Madrid, Pamplona, Seville, Valencia, and Zaragoza, SpainSee the 11 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors that carry a KRAS G12C mutation and were treated before. Lung, colorectal and pancreatic cancers are included.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced or metastatic solid tumor with a KRAS G12C mutation, not open to treatment meant to remove all of the disease. ECOG performance status 0 or 1.
- Earlier treatment
- Solid tumors must have been treated before. For one part of the study, lung cancer must have been treated with immunotherapy, chemotherapy and KRAS G12C (OFF) inhibitors. Other solid tumors must not have had KRAS G12C (OFF) inhibitors.
- Biomarker or test result
- KRAS G12C mutation, documented by pathology.
Main reasons for not taking part
- Primary central nervous system (CNS) tumors
- Active brain metastases
- Known problem of the gut that would change how drugs are absorbed
- Major surgery within 28 days before treatment
- Minor procedures not related to the study within 7 days before treatment
Read by machine on 9 November 2026.
Where in Spain
- Institut Catala d'Oncologia HospitalBarcelona, SpainTaking people
- START Barcelona Hospital HM Nou DelfosBarcelona, SpainTaking people
- Fundacion MD Anderson Cancer CenterMadrid, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- NEXT Oncology - Quirónsalud Madrid University HospitalMadrid, SpainTaking people
- START MadridMadrid, SpainTaking people
- University Clinic of NavarraMadrid, SpainTaking people
- University Clinic of NavarraPamplona, SpainTaking people
- Hospital Universitario Virgen MacarenaSeville, SpainTaking people
- La Fe University and Polytechnic HospitalValencia, SpainTaking people
- Hospital Universitario Miguel ServetZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06128551
- Record updated
- 22 September 2026
- Original description
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.Read full original descriptionShow less
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Inclusion: 18 years of age; Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy; Phase 1b Dose Escalation: solid tumors, previously treated; Phase 1b Dose Expansion and Phase 2:; NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors; ECOG performance status 0 or 1; Adequate organ function.
Exclusion: Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment; Known impairment of GI function that would alter the absorption; Primary central nervous system (CNS) tumors; Active brain metastases.